Current Report Filing (8-k)
March 10 2023 - 4:08PM
Edgar (US Regulatory)
0001821586
false
00-0000000
0001821586
2023-03-10
2023-03-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 10, 2023
MOONLAKE IMMUNOTHERAPEUTICS
(Exact name of registrant as specified in its charter)
Cayman Islands |
|
001-39630 |
|
N/A |
(State or other jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
of incorporation) |
|
|
|
Identification No.) |
Dorfstrasse 29 |
|
|
Zug, Switzerland |
|
6300 |
(Address of principal executive offices) |
|
(Zip Code) |
41 415108022
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Securities Exchange
Act of 1934:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Class A ordinary share, par value $0.0001 per share |
|
MLTX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
MoonLake Immunotherpeutics (the “Company”) is aware of
media reports indicating California’s banking regulator has taken possession of Silicon Valley Bank (“SVB”). The Company
informs its investors that it does not hold cash deposits or securities with SVB.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MoonLake Immunotherapeutics |
|
|
Date: March 10, 2023 |
By: |
/s/ Matthias Bodenstedt |
|
Name: |
Matthias Bodenstedt |
|
Title: |
Chief Financial Officer |
2
Helix Acquisition (NASDAQ:HLXA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Helix Acquisition (NASDAQ:HLXA)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Helix Acquisition Corp (NASDAQ): 0 recent articles
More Moonlake Immunotherapeutics News Articles